title: Hydroxypropyl-β-cyclodextrin functionalized calcium carbonate microparticles as a potential carrier for enhancing oral delivery of water-insoluble drugs.
abstract: The objective of the present study was to demonstrate that a novel hydroxypropyl-β-cyclodextrin functionalized calcium carbonate (HP-β-CD/CC) based amorphous solid dispersion (ASD) can be used to increase the solubility and oral bioavailability of water-insoluble drugs. Irbesartan (IRB) was selected as a model compound and loaded into the nanoporous HP-β-CD/CC matrix using an immersion method. The IRB-loaded HP-β-CD/CC formulation was characterized by various analytical techniques, such as specific surface area analysis, scanning electron microscopy (SEM), dynamic light scattering (DLS), powder X-ray diffraction (PXRD), and differential scanning calorimetry (DSC). Analyses with PXRD and DSC confirmed that IRB was fully converted into the amorphous form in the nanopores of HP-β-CD/CC. From the solubility and dissolution tests, it was observed that the aqueous solubility and dissolution rate of IRB-loaded HP-β-CD/CC were increased significantly compared with those of pure IRB and IRB-loaded mesoporous silica. Likewise, the IRB-loaded HP-β-CD/CC formulation exhibited better absorption compared with that of the commercially available IRB capsules in beagle dogs. The mean peak plasma concentration (C max) and the area under the mean plasma concentration-time curve (AUC[0→48]) of IRB-loaded HP-β-CD/CC were 1.56- and 1.52-fold higher than that of the commercial product, respectively. Furthermore, the IRB-loaded HP-β-CD/CC formulation exhibited excellent stability against re-crystallization. These results clearly demonstrate that HP-β-CD/CC based porous ASD is a promising formulation approach to improve the aqueous solubility and the in vivo absorption performance of a water-insoluble compound like IRB.
authors.affiliation: Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical College, Xuzhou, People's Republic of China.
authors.forename: Lihua
authors.initials: L
authors.lastname: Zhang
authors.affiliation: School of Pharmacy, Jiangxi Science and Technology Normal University, Nanchang, People's Republic of China.
authors.forename: Wufu
authors.initials: W
authors.lastname: Zhu
authors.affiliation: Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical College, Xuzhou, People's Republic of China.
authors.forename: Qisi
authors.initials: Q
authors.lastname: Lin
authors.affiliation: Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical College, Xuzhou, People's Republic of China.
authors.forename: Jin
authors.initials: J
authors.lastname: Han
authors.affiliation: Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical College, Xuzhou, People's Republic of China.
authors.forename: Liqun
authors.initials: L
authors.lastname: Jiang
authors.affiliation: Jiangsu Key Laboratory of New Drug Research and Clinical Pharmacy, Xuzhou Medical College, Xuzhou, People's Republic of China ; Department of Pharmaceutics, School of Pharmacy, Xuzhou Medical College, Xuzhou, People's Republic of China.
authors.forename: Yanzhuo
authors.initials: Y
authors.lastname: Zhang
mesh_terms: D000073738:2-Hydroxypropyl-beta-cyclodextrin; D000284:Administration, Oral; D000818:Animals; D001713:Biphenyl Compounds / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics; D002119:Calcium Carbonate / Q000737:chemistry*; D004285:Dogs; D004337:Drug Carriers / Q000737:chemistry*; D000077405:Irbesartan; D012995:Solubility; D013777:Tetrazoles / Q000097:blood / Q000737:chemistry / Q000493:pharmacokinetics; D047392:beta-Cyclodextrins / Q000737:chemistry*
chemical_list: D001713:Biphenyl Compounds; D004337:Drug Carriers; D013777:Tetrazoles; D047392:beta-Cyclodextrins; D000073738:2-Hydroxypropyl-beta-cyclodextrin; D002119:Calcium Carbonate; D000077405:Irbesartan
keywords: bioavailability; dissolution rate; nanopore; solid dispersion; solubility